Combination of IDO/Survivin Peptide Vaccine, GM-CSF, Imiquimod and Temozolomide Chemotherapy for Patients With Metastatic Malignant Melanoma

Trial Profile

Combination of IDO/Survivin Peptide Vaccine, GM-CSF, Imiquimod and Temozolomide Chemotherapy for Patients With Metastatic Malignant Melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2015

At a glance

  • Drugs Imiquimod (Primary) ; IO 101 (Primary) ; Temozolomide (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Aug 2012 Actual initiation date (May 2012) added as reported by ClinicalTrials.gov.
    • 13 Aug 2012 Planned End Date changed from 1 Sep 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 12 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top